679818-59-8
Post Buying Request-
-
Basic information
- Product Name: ofatumumab
- Synonyms: ofatumumab
- CAS NO:679818-59-8
- Molecular Formula:
- Molecular Weight: 0
- EINECS: N/A
- Product Categories: N/A
- Mol File: 679818-59-8.mol
- Article Data: 0
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: ofatumumab(CAS DataBase Reference)
- NIST Chemistry Reference: ofatumumab(679818-59-8)
- EPA Substance Registry System: ofatumumab(679818-59-8)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 679818-59-8(Hazardous Substances Data)
679818-59-8 Suppliers
Recommended suppliersmore
679818-59-8 Usage
Description
Considered as the most common form of leukemia in adults, CLL is characterized by the accumulation of abnormal B lymphocytes and manifests itself as lymph node enlargement and bone marrow failure in symptomatic patients. Ofatumumab is the second marketed mAb to target CD20. Compared to its predecessor,it is a fully human mAb that was generated via transgenic mouse and hybridoma technology. In addition to the Fab portion that recognizes CD20, the Fc domain mediates immune effector functions to lyse cells via complement-dependent cytotoxicity (CDC) and antibody-dependent, cell-mediated cytotoxicity (ADCC). Ofatumumab targets a different, discontinuous epitope on CD20 than rituximab; it binds specifically to both the small and large extracellular loops of the CD20 molecule expressed on normal B lymphocytes and on B-cell CL, and its binding does not induce receptor internalization nor shedding from the cell surface. In addition to targeting a different epitope on CD20, ofatumumab also exhibits a slower off-rate. These characteristics have been proposed as reasons for its ability to lyse rituximab-resistant cells that express low levels of CD20 and for its greater in vitro activity against CLL cells versus rituximab.The most common adverse events were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.Originator
Genmab (Denmark)Brand name
ArzerraClinical Use
IgG1 monoclonal antibody: Treatment of chronic lymphocytic leukaemiaMetabolism
Ofatumumab is eliminated by proteolytic enzymes and via binding to B-cells.Check Digit Verification of cas no
The CAS Registry Mumber 679818-59-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,9,8,1 and 8 respectively; the second part has 2 digits, 5 and 9 respectively.Calculate Digit Verification of CAS Registry Number 679818-59:
(8*6)+(7*7)+(6*9)+(5*8)+(4*1)+(3*8)+(2*5)+(1*9)=238
238 % 10 = 8
So 679818-59-8 is a valid CAS Registry Number.
679818-59-8Upstream product
679818-59-8Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 679818-59-8
ofatumumab
